GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

Lifesciences | Healthcare & Wellness

GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

Market by Therapeutics & Diagnostics and Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

The global Alzheimer’s disease therapeutics and diagnostics market is projected to exhibit an upward trend by progressing at a CAGR of 7.78% throughout the estimated period of 2019 to 2027.

Alzheimer's disease is a type of dementia that causes problems like memory degradation, along with behavioral and thinking changes. The disease develops slowly and worsens as time progresses. Recently, Alzheimer’s was found to be the sixth leading cause of death in the United States. People with Alzheimer's, on an average, live for eight years after their symptoms become visible, but this can range from four to twenty years, depending on the individual’s age and other health conditions. 


As per the Alzheimer’s Association data for the year 2016, an estimated 5.4 million Americans of all ages have been diagnosed with Alzheimer's disease. One in nine individuals aged 65 and above has been diagnosed with Alzheimer's. As per the Alzheimer’s Disease International data for 2015, there are an estimated 46.8 million individuals worldwide living with dementia and this trend is further expected to grow in future due to the rising aging population across the world, thanks to the improved life expectancy. Hence, there is an increasing demand for Alzheimer’s therapeutics and diagnostics globally. 

Recent developments in research have enhanced the understanding and diagnosis of neurological disorders. The rise in the utilization of techniques such as biomarkers and positron emission tomography has facilitated the radiologists to analyze the amyloid plaques that are specific to Alzheimer’s patients. These developments have enabled researchers to eradicate "trial and error" prescription, ushering the development of personalized medicine for Alzheimer’s. Also, the surge in funding for the advancement of personalized medicines has aided in promoting the growth of therapeutics being adopted in Alzheimer’s disease. Also, investments in personalized medicines in the US have grown by over xx% during 2012-2016. 

The various components studied within the global Alzheimer’s disease therapeutics market report are Porter’s five force model, etymology, parent market outlook, strategic buying criteria outlook, investments outlook, key findings, industry structure, regulatory framework and agency. Also, etiology and pipeline outlook, phases and sternness of disease have been studied in the report.

Factors such as the growing prevalence of Alzheimer’s disease, increasing geriatric population and the substantial increase in the investments made by governments are the top factors contributing to the growth of the market globally. However, restraints like strict government regulations and the increased expenses for the treatments are responsible for obstructing the market growth globally. Opportunities like in-vitro diagnostics techniques and rising investments in the R&D of personalized medicines are leveraging the market to proliferate towards the projected growth over the coming years. However, low awareness about new therapies and very few professionals available for the treatment are the major challenges faced by the market.

The major regions covered in the global Alzheimer’s disease therapeutics and diagnostics market are:

•    North America: United States and Canada

•    Europe: United Kingdom, Germany, France, Spain, Italy, Russia and Rest of Europe

•    Asia-Pacific: China, Japan, India, Australia & New Zealand, South Korea, ASEAN countries and Rest of Asia-Pacific

•    Latin America: Brazil, Mexico and Rest of Latin America

•    The Middle East and Africa: United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of the Middle East and Africa

The global Alzheimer’s disease therapeutics and diagnostics market is segmented as follows: 

•    Therapeutics and Diagnostics:

O    Therapeutics 

•        Drugs - Market Drugs and Pipeline Drugs

•        Disease Stage - Late Stage: Severe AD and Early/Middle Stage: Mild to Moderate AD

•        Prodromal Stage

•        Generic and Branded

O    Diagnostics

•        Lumbar Puncture Test

•        Positron Emission Tomography

•        Electroencephalography

•        Magnetic Resonance Imaging

•        Computed Tomography

•        Other Diagnostics


The major players operating in the global Alzheimer’s disease therapeutics and diagnostics market include GE Healthcare, Merck and Co., Baxter, Biogen, DiaGenic ASA, Cognoptix, Roche, AXON Neuroscience SE, Sun Pharmaceutical Industries Ltd., AbbVie, Siemens Healthineers AG, Amarantus BioScience Holdings Inc., Piramal Enterprises Ltd., and Johnson & Johnson.

The strategic analysis for each of these companies in the global Alzheimer’s disease therapeutics and diagnostics market has been covered in this report. The market share of the company guides with information about the top players and their presence in the market has been provided.


Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH AND DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END USER

2.9.5. WHOLESALERS

2.10. REGULATORY FRAMEWORK

2.11. THE UNITED STATES AND EUROPE REGULATORY AGENCY

2.12. ALZHEIMER'S DISEASE ETIOLOGY

2.13. PIPELINE OUTLOOK

2.14. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

2.15. MARKET DRIVERS

2.15.1. GROWTH OF THE ALZHEIMER’S DISEASE

2.15.2. GROWING GERIATRIC POPULATION

2.15.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.16. MARKET RESTRAINTS

2.16.1. STRINGENT GOVERNMENT REGULATIONS

2.16.2. THE TREATMENT OF ALZHEIMER’S DISEASE COSTS VERY HIGH

2.17. MARKET OPPORTUNITIES

2.17.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.17.2. R&D INVESTMENT IN THE PERSONALIZED MEDICINES IS INCREASING

2.18. MARKET CHALLENGES

2.18.1. AWARENESS IS LESS CONCERNING NEW THERAPIES IN THE ALZHEIMER’S DISEASE

2.18.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER’S DISEASE

3.    ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK - BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.3. PRODROMAL STAGE

3.1.4. THERAPEUTICS BY GENERIC AND BRANDED

3.1.4.1. BRANDED

3.1.4.2. GENERIC

3.2. DIAGNOSTIC TYPE

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4.    ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – REGIONAL OUTLOOK

4.1. NORTH AMERICA

4.1.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.1.2. COUNTRY ANALYSIS

4.1.2.1. THE UNITED STATES

4.1.2.2. CANADA

4.2. EUROPE

4.2.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.2.2. COUNTRY ANALYSIS

4.2.2.1. THE UNITED KINGDOM

4.2.2.2. FRANCE

4.2.2.3. GERMANY

4.2.2.4. SPAIN

4.2.2.5. ITALY

4.2.2.6. RUSSIA

4.2.2.7. REST OF EUROPE

4.3. ASIA-PACIFIC

4.3.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.3.2. COUNTRY ANALYSIS

4.3.2.1. CHINA

4.3.2.2. INDIA

4.3.2.3. JAPAN

4.3.2.4. AUSTRALIA AND NEW ZEALAND

4.3.2.5. SOUTH KOREA

4.3.2.6. ASEAN COUNTRIES

4.3.2.7. REST OF ASIA-PACIFIC

4.4. LATIN AMERICA

4.4.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.4.2. COUNTRY ANALYSIS

4.4.2.1. BRAZIL

4.4.2.2. MEXICO

4.4.2.3. REST OF LATIN AMERICA

4.5. MIDDLE EAST AND AFRICA

4.5.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.5.2. COUNTRY ANALYSIS

4.5.2.1. SAUDI ARABIA

4.5.2.2. TURKEY

4.5.2.3. UNITED ARAB EMIRATES

4.5.2.4. SOUTH AFRICA

4.5.2.5. REST OF MIDDLE EAST & AFRICA

5.    COMPANY PROFILES

5.1. ABBVIE

5.2. AMARANTUS BIOSCIENCE HOLDINGS, INC.

5.3. AXON NEUROSCIENCE SE

5.4. BAXTER

5.5. BIOGEN

5.6. COGNOPTIX

5.7. DIAGENIC ASA

5.8. ROCHE

5.9. GE HEALTHCARE

5.10. MERCK

5.11. JOHNSON & JOHNSON

5.12. PIRAMAL ENTERPRISES LTD.

5.13. SIEMENS HEALTHINEERS AG

5.14. SUN PHARMACEUTICAL INDUSTRIES LTD.

6.    RESEARCH METHODOLOGY & SCOPE

6.1. RESEARCH SCOPE & DELIVERABLES

6.1.1. OBJECTIVES OF STUDY

6.1.2. SCOPE OF STUDY

6.2. SOURCES OF DATA

6.2.1. PRIMARY DATA SOURCES

6.2.2. SECONDARY DATA SOURCES

6.3. RESEARCH METHODOLOGY

6.3.1. EVALUATION OF PROPOSED MARKET

6.3.2. IDENTIFICATION OF DATA SOURCES

6.3.3. ASSESSMENT OF MARKET DETERMINANTS

6.3.4. DATA COLLECTION

6.3.5. DATA VALIDATION & ANALYSIS

           

            

List of table

TABLE 1        GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE 2        GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

TABLE 3        GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2019-2027 ($ MILLION)

TABLE 4        GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2019-2027 ($ MILLION)

TABLE 5        GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2019-2027 ($ MILLION)

TABLE 6        GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET BY DIAGNOSTIC TYPE 2019-2027 ($ MILLION)

TABLE 7        GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE 8        NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 ($ MILLION)

TABLE 9        NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE 10      EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 ($ MILLION)

TABLE 11      EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE 12      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 ($ MILLION)

TABLE 13      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE 14      LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 ($ MILLION)

TABLE 15      LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE 16      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 ($ MILLION)

TABLE 17      MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)

            

List of Figures

FIGURE 1      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 2      INVESTMENTS IN ALZHEIMER’S DISEASE TREATMENT

FIGURE 3      ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 4      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 ($ MILLION)

FIGURE 5      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 ($ MILLION)

FIGURE 6      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 ($ MILLION)

FIGURE 7      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 ($ MILLION)

FIGURE 8      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 ($ MILLION)

FIGURE 9      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 ($ MILLION)

FIGURE 10   GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 ($ MILLION)

FIGURE 11   GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 ($ MILLION)

FIGURE 12   GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTIC TYPE 2019-2027 ($ MILLION)

FIGURE 13   GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 ($ MILLION)

FIGURE 14   GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 ($ MILLION)

FIGURE 15   GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 ($ MILLION)

FIGURE 16   GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 ($ MILLION)

FIGURE 17   GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 ($ MILLION)

FIGURE 18   GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 ($ MILLION)

FIGURE 19   THE UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 20   CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 21   EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027 ($ MILLION)

FIGURE 22   THE UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 23   FRANCE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 24   GERMANY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 25   SPAIN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 26   ITALY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 27   RUSSIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 28   REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 29   ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 30   CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 31   INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 32   JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 33   AUSTRALIA AND NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 34   SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 35   ASEAN COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 36   REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 37   LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 38   BRAZIL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 39   MEXICO ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 40   REST OF LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 41   MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 42   SAUDI ARABIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 43   TURKEY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 44   UNITED ARAB EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 45   SOUTH AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 46   REST OF MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$2,750.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$4,000.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;